Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$180.96 USD
+2.38 (1.33%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $180.89 -0.07 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$180.96 USD
+2.38 (1.33%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $180.89 -0.07 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Charles River (CRL) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
The service business within Charles River (CRL) RMS is expected to have witnessed growth in the fourth quarter, banking on small molecule revenue increase across several geographic regions.
Charles River (CRL) Launches Animal-Free Endotoxin Test
by Zacks Equity Research
Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.
Charles River's (CRL) New Launch to Boost Gene Therapy Programs
by Zacks Equity Research
Charles River's (CRL) latest offering is likely to complete a comprehensive range of off-the-shelf plasmid products and simplify gene therapy supply chains with immediate availability.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.
Charles River's (CRL) Memphis Site Achieves Crucial Approval
by Zacks Equity Research
Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.
Charles River (CRL) Expands 3D In Vitro Services Via New Deal
by Zacks Equity Research
Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.
Charles River (CRL) Up 19.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.
Charles River (CRL) Gains on Price & Volume Growth Amid FX Woe
by Zacks Equity Research
At present, Charles River (CRL) is the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.
Charles River (CRL) Backs the Quest to Cure SPG56 via New Deal
by Zacks Equity Research
Charles River (CRL) and GC4K announce a gene therapy manufacturing collaboration.
Charles River (CRL) Widens CliniPrime GMP Suite With New Launch
by Zacks Equity Research
Charles River (CRL) brings CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.
Charles River (CRL) to Advance AI Drug Discovery With New Pact
by Zacks Equity Research
Charles River's (CRL) recent partnership will enable the optimization of the discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.
Charles River's (CRL) Q3 Earnings Beat, Margins Decline
by Zacks Equity Research
Charles River's (CRL) RMS organic revenue growth is primarily driven by research model services, particularly the Insourcing Solutions business.
Charles River (CRL) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Unlocking Q3 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Charles River (CRL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.
Earnings Preview: Charles River Laboratories (CRL) Q3 Earnings Expected to Decline
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River (CRL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Charles River's (CRL) CRADLE initiative and research models in North America and China are anticipated to have maintained their growth momentum in the third quarter.
Why Charles River (CRL) Could Beat Earnings Estimates Again
by Zacks Equity Research
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charles River (CRL) Offers Access to Preclinical Cancer Research
by Zacks Equity Research
Charles River (CRL) contributes to 84 percent of the FDA-approved cancer medicines and provides partners with 16 oncology prospects.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on robust RMS segment growth and upbeat guidance.
Charles River (CRL) Launches LVV-based Gene Therapy Platform
by Zacks Equity Research
Charles River's (CRL) LVV platform provides medicinal developers with an efficient, dependable route to the clinic and the market.
Charles River (CRL) Opens a RightSource Lab in Stevenage
by Zacks Equity Research
Charles River's (CRL) new RightSource facility is likely to provide services to the Stevenage advanced therapy biocluster.
Charles River (CRL) Announces Partnership With Related Sciences
by Zacks Equity Research
Charles River's (CRL) new collaboration is likely to leverage the AI-powered drug discovery and development platform, Logica.
Charles River (CRL) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on the RMS segment's continued growth and upbeat guidance.